Icon (ICLR) Stock Price, News & Analysis

Company Overview

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence. ICON also provides strategic consulting and commercialization support, helping clients address operational, scientific and regulatory requirements across the product life cycle.

Founded in Dublin, Ireland, in 1990, ICON has expanded into a global organization serving clients across North America, Europe, Asia-Pacific and other international markets. The company became a publicly traded company on Nasdaq in 1998 and significantly expanded its capabilities through the acquisition of PRA Health Sciences in 2021.

ICON is led by Chief Executive Officer Steve Cutler, who has held the role since 2017. Its broad international operations and range of outsourced development services position the company as a partner for organizations conducting clinical research and developing innovative healthcare products.

Key Stats

• Today's Range: $169.44 to $177.50
• 50-Day Range: $156.70 to $180.24
• 52-Week Range: $66.57 to $203.91
• Volume: 1.17 million shs
• Average Volume: 704,163 shs
• Market Capitalization: $12.99 billion
• P/E Ratio: 39.83
• Dividend Yield: N/A
• Price Target: $170.40
• Consensus Rating: Hold

Icon Stock Analysis - MarketRank™

Icon scored higher than 52% of companies evaluated by MarketBeat, and ranked 628th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Icon has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 1 strong buy rating, 7 buy ratings, 7 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Icon is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Icon has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.94%

Earnings Growth

Earnings for Icon are expected to grow by 12.94% in the coming year, from $9.58 to $10.82 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Icon is 39.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.68.

Price to Earnings Ratio vs. Sector

The P/E ratio of Icon is 39.83, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.27.

Price to Earnings Growth Ratio

Icon has a PEG Ratio of 8.03. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Icon has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.55% of the float of Icon has been sold short.

Short Interest Ratio / Days to Cover

Icon has a short interest ratio ("days to cover") of 5.01.

Change versus previous month

Short interest in Icon has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Icon does not currently pay a dividend.

Dividend Growth

Icon does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Icon has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Icon this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for ICLR on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Icon to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Icon insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,565,764.00 in company stock.

Percentage Held by Insiders

44.00% of the stock of Icon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

95.61% of the stock of Icon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/18/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:ICLR
• Previous Symbol: NASDAQ:ICLR
• CIK: 1060955
• Web: www.iconplc.com
• Phone: (531) 291-2000
• Fax: 353-1247-6260
• Employees: 40,100
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Icon: $170.40
• High Price Target: $209.00
• Low Price Target: $100.00
• Potential Upside/Downside: +0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.41
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.26
• Trailing P/E Ratio: 39.83
• Forward P/E Ratio: 17.71
• P/E Growth: 8.03
• Net Income: $229.34 million
• Net Margins: 3.99%
• Pretax Margin: 1.31%
• Return on Equity: 8.02%
• Return on Assets: 4.56%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 0.95
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: $8.29 billion
• Price / Sales: 1.57
• Cash Flow: $16.44 per share
• Price / Cash Flow: 10.32
• Book Value: $120.07 per share
• Price / Book: 1.41

Miscellaneous

• Outstanding Shares: 76,567,000
• Free Float: 42,878,000
• Market Cap: $12.99 billion
• Optionable: Optionable
• Beta: 1.20